No coverage by Medicare and Medicaid.

H1 results in line with profit warning posted 2 weeks ago.

Leonardo upgraded to add and estimates revised up.

Headwinds ahead lead us to sharp cut in estimates.

Another deal in obesity strengthens Novo’s position in the field.

Feud at Mediobanca brings uncertainty ahead of the key board on April 24th.